Active Ingredient History
Goserelin is a synthetic decapeptide analogue of LHRH. Goserelin acts as a potent inhibitor of pituitary gonadotropin secretion when administered in the biodegradable formulation. The result is sustained suppression of LH and serum testosterone levels. Goserelin is used to treat hormone-sensitive cancers of the breast (in pre- and peri- menopausal women) and prostate, and some benign gynaecological disorders (endometriosis, uterine fibroids and endometrial thinning). In addition, goserelin is used in assisted reproduction and in the treatment of precocious puberty. Goserelin is marketed under the brand names Zoladex, by AstraZeneca, or goserelin acetate. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Prostatic Neoplasms (approved 1997)
Androgens (Phase 3)
Anemia (Phase 3)
Azoospermia (Phase 2)
Breast Diseases (Phase 2/Phase 3)
Breast Neoplasms (Phase 4)
Breast Neoplasms, Male (Phase 3)
Bulbo-Spinal Atrophy, X-Linked (Phase 4)
Carcinoma (Phase 2)
Cardiovascular Diseases (Phase 4)
Castration (Phase 3)
Drug Evaluation (Phase 2/Phase 3)
Drug Therapy (Phase 2/Phase 3)
Endometriosis (Phase 4)
Fallopian Tube Neoplasms (Phase 2)
Hamartoma (Phase 2)
Hot Flashes (Phase 3)
Infertility (Phase 4)
Inflammatory Breast Neoplasms (Phase 2/Phase 3)
Intestinal Neoplasms (Phase 3)
Leiomyoma (Phase 4)
Menopause (Phase 3)
Metabolic Syndrome (Phase 2)
Muscle Hypotonia (Phase 3)
Muscular Atrophy (Phase 3)
Neoplasm Metastasis (Phase 3)
Neoplasms (Phase 2)
Osteoporosis (Phase 3)
Ovarian Diseases (Phase 3)
Ovarian Neoplasms (Phase 2)
Primary Ovarian Insufficiency (Phase 2)
Prostatic Neoplasms (Phase 4)
Salivary Gland Neoplasms (Phase 2)
Sarcopenia (Phase 3)
Sexual Dysfunction, Physiological (Phase 3)
Therapeutic Equivalency (Phase 1)
Urination Disorders (Phase 3)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue